JUPW - Jupiter Wellness’s Potential New OTC Drug Could Put Some More Joy Back Into Breast Cancer Survivors’ Lives
(NewsDirect)
Learn More aboutJupiter Wellness Inc. by gaining access to the latest researchreport
Breast cancer has surpassed lung cancer as the mostcommonly diagnosed cancer globally as of 2021, according to theAmerican Cancer Society and the International Agency for Research onCancer.
Although breast cancer is oneof the more talked-about cancers, there are many disturbing factsrelated to this deadly disease that make it more alarming than othercancers.
Stats Show Breast Cancer Continues To Wreak Havoc OnWomen’s Lives
Here are some of thelatest stats :
-
About 1 in 8 U.S. women (about 13%) will develop invasivebreast cancer over the course of their lifetimes.
-
As of January 2022, there are more than 3.8million women with a history of breast cancer in the U.S., includingwomen currently being treated and women who have finishedtreatment.
-
In 2022, anestimated 287,850 new cases of invasive breast cancer are expected tobe diagnosed in women in the U.S.
-
Breast cancer affects men, too, and about 2,710 new cases ofinvasive breast cancer are expected to be diagnosed in men in 2022with a man’s lifetime risk of breast cancer being about 1 in833.
-
About 43,250 women inthe U.S. are expected to die of breast cancer in 2022.
-
Death rates have been steady in women under50 since 2007 but have continued to drop in women over 50 because ofscreening and early detection and care.
-
About 85% of breast cancers occur in womenwho have no family history of breast cancer. These occur because ofgenetic mutations that happen as a result of the aging process andlifestyle — less than 15% of women who get breast cancer have afamily member diagnosed with it.
Several pharmaceutical companies including Bristol-Myers Squibb Co. (NYSE: BMY), Merck & Co. Inc. (NYSE: MRK), Medivation Inc. (NASDAQ: MDVN), and PfizerInc. (NYSE: PFE) have reported developing breakthrough drugs totreat breast cancer over the years. And considerable progress has beenmade in reducing cancer rates and improving cancer survival throughimproved diagnostic and treatment modalities, according to reports.
Yet the adverseeffects of cancer treatment continue to cause concern and unhappinessfor breast cancer survivors.
Following breast cancer treatment or surgery, somewomen experience a number of side effects, including a change in bodyweight, tightness of the skin, changes in sensation, phantom breastsensations (in surgery patients), and loss of sexual desire(libido).
The sexual health of womenand female libido have always been awkward topics of conversation thatare seldom discussed openly. Women don’t want to talk about it andit seems little attention has been paid to developing drugs cateringto female sexual wellness. And, by extension, their male partners.
A Side Effect That Could Regenerate Libido? Spark Joy?
But one Florida-basedBioPharma company has licensed a breakthrough product with a novelmechanism of action for women’s sexual wellness. As per a recent pressrelease, “The exclusive license includes issued patents andtechnology, including formulations. In clinical studies, one topicalformulation improved nipple sensitivity and alleviated associatedsexual problems. Concomitantly, the formulation was also shown toincrease female sexual lubrication and improve overall orgasmicresponse.”
Jupiter Wellness Inc. (NASDAQ: JUPW) reports that itsproposed drug, JW-500, when topically applied to the nipple-areolaarea of the breast, contracts the smooth muscle, thus erecting thenipple and increasing its sensitivity.
The company reports that clinical trials ofJW-500 have shown efficacy and safety in improving female nipplesensitivity. Further testing is being conducted to quantify andqualify enhanced sexual arousal, vaginal lubrication, and orgasmresponse in healthy women and women suffering from nipple naturopathyfollowing breast cancer treatment.
"This treatment has the potential to address awide range of clinical indications, including nipple neuropathiesfollowing breast augmentation in breast cancer survivors”, saidJupiter Wellness CEO Brian John."We are excited to complete theresearch and development of this product and to bring this novelapproach to the market. I believe this product may not only be anexcellent treatment for people with breast cancer but potentially as awomen's sexual health product as well."
The company plans tofile for a pre-IND meeting with the US FDA within the next 12 monthsand intends to seek Orphan Drug Designation for JW-500. Consideringthe size of the market for breast cancer survivors and the possibilityof addressing libido loss in post-menopausal women, Jupiter Wellnessmay be a company to keep an eye out for news on their clinicalprogress.
Tolearn more about JW-500 and Jupiter Wellness, visit its webpage .
We supporthealth and wellness through the research and development ofover-the-counter (OTC) products and intellectual property. Our productpipeline addresses a range of conditions, including hair loss, eczema,burns, and sexual wellness. Revenue is generated through the sales ofOTC and consumer products, contract research agreements, and licensingroyalties.
This post contains sponsored advertising content.This content is for informational purposes only and is not intended tobe investing advice.
ContactDetails
TraDigital IR- Camille Baptiste
CompanyWebsite
Copyright (c) 2022 TheNewswire - All rights reserved.